Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

High Potency Drug Market worth USD 379.20 Billion by 2031 - Says InsightAce Analytic

This image opens in the lightbox

News provided by

InsightAce Analytic Pvt. Ltd

30 May, 2024, 14:01 GMT

Share this article

Share toX

Share this article

Share toX

JERSEY CITY, N.J., May 30, 2024 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "High Potency Drug Market - By Product Type (Innovative and Generic), Dosage Form (Injectables, Oral Solids, Creams), Manufacturer Type (In-House and Outsourced). Therapeutic Area (Oncology, Hormonal Imbalance, Neurology), By Distribution Channel, By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the High Potency Drug Market is valued at US$ 169.42 Bn in 2023, and it is expected to reach US$ 379.20 Bn by 2031, with a CAGR of 10.7% during the forecast period of 2024-2031.

High potency drugs are a growing segment in the pharmaceutical industry, characterized by their powerful biological activity and specificity. These drugs are designed to have a significant therapeutic effect at very low doses, often measured in micrograms or nanograms. This unique property makes them particularly useful for treating severe and life-threatening conditions such as cancer, where the intent is to deliver precise and targeted treatment to minimize side effects.

Request for Free Sample Pages: https://www.insightaceanalytic.com/request-sample/2505

These drugs are pivotal across diverse medical landscapes, ranging from cancer to asthma and pain management. Engineered with a high therapeutic index, they enable precise, low-dose administration without significant side effects. This targeted approach is a boon for patients requiring meticulous and effective treatment strategies, indicating a new era in pharmaceutical advancement. The driving force behind the prominence of high-potency drugs is the urgent need for more effective treatments with reduced side effects, especially in the realm of cancer therapy.

List of Prominent Players in the Lab Workflow Optimization Market:

  • Hoffmann-La Roche Ltd
  • Johnson & Johnson Services, Inc.
  • GSK plc.
  • Pfizer Inc.
  • AbbVie Inc.
  • F. AstraZeneca plc
  • Merck & Co., Inc.
  • Novartis AG
  • Bristol-Myers Squibb Co
  • Sanofi
  • Takeda Pharmaceutical Co Ltd.
  • Eli Lilly and Company
  • Gilead Sciences
  • Amgen
  • Bayer AG

Lab Workflow Optimization Market Report Scope:

Report Attribute

Specifications

Market Size Value in 2023

USD 169.42 Bn

Market Size Value in 2031

USD 379.20 Bn

Growth Rate CAGR

CAGR of 10.7% from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Bn and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Product Type, Dosage Form, Therapeutic Area, Manufacturer Type, Distribution Channel

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa


Order 180 Pages Full Report @
 https://www.insightaceanalytic.com/buy-report/2505

Market Dynamics:

Drivers:

Advances in oncology treatments, particularly the rise of targeted therapies, are driving the expansion of the high potency drug market. These therapies often rely on potent and precise drugs to achieve optimal outcomes, driving the demand for high potency drugs.  According to American Cancer Society (ACS) estimates, in 2023, the United States is anticipated to have 1,958,310 new cancer cases and 609,820 cancer deaths, further highlighting the demand for high-potency drugs.

Moreover, Personalized precision medicine, designed for individuals' genetic profiles and lifestyles, is another significant driver. This approach not only enhances treatment effectiveness across various diseases, including cancer, neurological disorders, and metabolic conditions but also streamlines drug development processes and leverages digital platforms for scalability, potentially amplifying the demand for high potency drugs customized to specific patient needs.

Challenges:

The demand for high potency drugs presents significant challenges within the pharmaceutical industry, primarily due to contract manufacturing organizations (CMOs) constraints. Despite the high demand, a limited number of CMOs are equipped to meet buyers' precise needs. These requirements include high production capacity, lyophilization capability, and extensive experience handling high potency drugs.

Additionally, manufacturing such drugs requires significant operating costs. This is attributed to the need for technical expertise, advanced technology, and specialized containment facilities, which necessitate substantial capital investment. Furthermore, stringent regulatory requirements stand as another barrier for CMOs in this space. Compliance with regulations governing high potency drugs, particularly regarding containment technology, dedicated facilities, and sophisticated equipment, presents a significant challenge for manufacturers.

Regional Trends:

North America, especially the United States, leads the way in the high potency drug market and is expected to stay on top in the future too. This is because the US has vital research centers and universities that help create new high potency drugs, especially for treating cancer and other specific conditions.

The US also has clear rules from the FDA, making it easier for drug companies to work here. Places like New Jersey, California, and the Midwest have lots of skilled workers who know how to make these powerful drugs. People in North America, especially in the US, really want new and targeted treatments, which boosts the use and development of high potency drugs even more. Plus, many drug companies are choosing to get these drugs made by particular manufacturers in North America, which adds to the region's dominance in this market.

Curious about this latest version of the report? @  https://www.insightaceanalytic.com/enquiry-before-buying/2505 

Recent Developments:

  • In April 2024, Novartis AG struck a licensing deal with Arvinas worth up to $1.01 billion for access to its experimental prostate cancer drug, ARV-766. Novartis paid an upfront fee of $150 million for global development and commercialization rights, with additional tiered royalties and milestone payments potentially reaching $1.01 billion, as reported by Reuters.
  • In November 2022, GSK opened its first high-potency manufacturing and testing facility in Singapore, investing S$44 million to strengthen its Jurong site. This facility will produce an essential ingredient for antibody-drug conjugates (ADCs), advancing next-generation cancer treatments and showcasing Singapore's growing prominence in pharmaceutical innovation.

Segmentation of High Potency Drug Market-

By Product Type

  • Innovative
  • Generic

By Dosage Form

  • Injectables
  • Oral Solids
  • Creams
  • Others (Foams, Gels & Inhalation)

By Manufacturer Type

  • In-house
  • Outsourced

By Therapeutic Area

  • Oncology
  • Hormonal Imbalance
  • Neurology
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

For More Customization @ https://www.insightaceanalytic.com/customisation/2505

Why should buy this report:

  • To receive a comprehensive analysis of the prospects for global High Potency Drug market
  • To receive industry overview and future trends of global High Potency Drug market
  • To analyze the High Potency Drug market drivers and challenges
  • To get information on the High Potency Drug market size value (US$ Mn) forecast till 2031.
  • Major Investments, Mergers & Acquisition in High Potency Drug market.

Other Related Reports Published by InsightAce Analytic:

Neuroimmunology Drugs Market

Immunology Drugs Market 

Next Generation Drug Conjugates Market 

Peptide And Anticoagulant Drugs Market 

Orphan Drugs Market

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact Us:

InsightAce Analytic PVT. LTD
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Follow us on LinkedIn: https://www.linkedin.com/company/insightace-analytic-pvt-ltd/

Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg

Modal title

Also from this source

Functional Service Providers (FSP) Market 2024-2031 | Transform Your Business Strategy with InsightAce Analytic Detailed Report

Functional Service Providers (FSP) Market 2024-2031 | Transform Your Business Strategy with InsightAce Analytic Detailed Report

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Functional Service Providers (FSP) Market- (By...

Sustainable Beauty and Skincare Market will Expand USD 326.8 Billion to 2031- Says Latest InsightAce Analytic Pvt. Ltd. Survey

Sustainable Beauty and Skincare Market will Expand USD 326.8 Billion to 2031- Says Latest InsightAce Analytic Pvt. Ltd. Survey

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Sustainable Beauty and Skincare Market'- By Type (Organic...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.